HOME >> MEDICINE >> NEWS
Study Pinpoints Effectiveness Of Prostate Cancer Therapies To Patient Populations

Outcomes Measured In Relation To Radical Prostectomy, External Beam Radiation, And Seen Implant Therapy

Philadelphia, PA--Implanting radioactive-filled seeds into a cancerous prostate gland has been a largely sucessful method of treating the second-leading cancer killer among men for more than two decades. However, a new study says that, after an estimated 41-month follow-up, patients classified as high-risk had a poorer outcome after being treated with the seed implant therapy compared to those who underwent either radical prostectomy or external beam radiation. These findings are published in the September 16, 1998 issue of the Journal of the American Medical Association (JAMA). The study also concluded that no significant difference in outcome was noted in low risk patients across all treatment modalities for this short and limited follow-up period.

"These results suggest that a particular population of patients -- those we can pre-therapeutically determine to be "high risk" -- don't do as well with the seed therapy as judged by prostate specific antigen (PSA) levels, as with alternative forms of therapy," says Alan Wein, MD, senior investigator on the study and chief of urology at the University of Pennsylvania Cancer Center.

Penn researchers used collected data from 1,872 men who were treated for their localized prostate cancer between 1989 and 1997. The men underwent one of three treatment options: radical prostectomy, external beam radiation, or seed implant therapy offered at two clinical sites.

The researchers set out to measure the rate of disease-free survival for these patients. In doing so, they used three tests: PSA, biopsy Gleason score, and the American Joint Commission on Cancer staging (AJCC) T-stage.

As background, PSA blood tests measure the level of prstate-specific antigens in the blood: the results are reported as nanograms per milli
'"/>

Contact: Sue Montgomery
smontgom@mail.med.upenn.edu
(215) 349-5657
University of Pennsylvania School of Medicine
16-Sep-1998


Page: 1 2

Related medicine news :

1. Study of energy and health in Africa focuses spotlight on charcoal and forest management
2. Study shows promise in identifying kidney failure
3. Study shows patch therapy may be as effective as oral medications
4. Study shows soy is well accepted in school lunches
5. Study finds that coordinating care of chronically ill patients does not increase liability
6. Study provides new estimates of the causes of child mortality worldwide
7. Study finds factors linked to substance use disorder relapse among health care professionals
8. Study finds majority of women willing to accept cervical cancer vaccine for self and children
9. Study shows use of budesonide reduced the risk of asthma related events by 40% in children
10. Study shows risk of cardiac death after radiation for breast cancer has dramatically decreased
11. Study shows acrylamide in baked and fried food does not increase risk of breast cancer in women

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:10/13/2017)... ... 2017 , ... “The Journey: From the Mountains to the Mission Field”: the ... in the Philippines. “The Journey: From the Mountains to the Mission Field” is the ... She has taught all ages and currently teaches a class of ladies at her ...
(Date:10/12/2017)... (PRWEB) , ... October 12, 2017 , ... ... are now treating sleep apnea using cutting-edge Oventus O2Vent technology. As ... serious sleep disorder characterized by frequent cessation in breathing. Oral appliances can offer ...
(Date:10/12/2017)... ... , ... IsoComforter, Inc. ( https://isocomforter.com ), one of the Nation’s ... design of the shoulder pad. The shoulder pad provides optimal support and full ... while using cold therapy. By utilizing ice and water that is circulated from an ...
(Date:10/12/2017)... ... October 12, 2017 , ... Information about the technology: ... develop to enable prevention of a major side effect of chemotherapy in children. ... pediatric patients. For cisplatin, hearing loss is FDA listed on-label as a dose ...
(Date:10/12/2017)... ... October 12, 2017 , ... Leading pediatric oncology experts ... Washington, D.C., for the 49th Congress of the International Society of Paediatric Oncology ... of the Center for Cancer and Blood Disorders at Children’s National, and ...
Breaking Medicine News(10 mins):
(Date:9/18/2017)... , Sept. 18, 2017 EpiVax, ... of bioinformatics and immune engineering, today announced ... influenza A (H7N9) vaccine. ... to seasonal influenza and presents a challenge ... prior exposure to be effective. Using state-of-the-art ...
(Date:9/12/2017)... NEW YORK , Sept. 12, 2017   EcoVadis ... global supply chains, has published the first annual edition of its Global ... more than 20,400 companies evaluated by EcoVadis, based on Scorecard Ratings that ... ... Risk & Performance Index ...
(Date:9/12/2017)... 12, 2017  ValGenesis Inc., the global leader ... pleased to announce the appointment of Dr. ... Board of Directors and Chairman of Advisory Board ... science companies to manage their entire validation lifecycle ... in this process. Furthermore, ValGenesis VLMS enables rigorous ...
Breaking Medicine Technology:
Cached News: